CA2971296A1 - Use of isoxazoline compounds for treating demodicosis - Google Patents
Use of isoxazoline compounds for treating demodicosis Download PDFInfo
- Publication number
- CA2971296A1 CA2971296A1 CA2971296A CA2971296A CA2971296A1 CA 2971296 A1 CA2971296 A1 CA 2971296A1 CA 2971296 A CA2971296 A CA 2971296A CA 2971296 A CA2971296 A CA 2971296A CA 2971296 A1 CA2971296 A1 CA 2971296A1
- Authority
- CA
- Canada
- Prior art keywords
- isoxazoline compound
- use according
- administered
- dogs
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199562 | 2014-12-22 | ||
| EP14199562.1 | 2014-12-22 | ||
| PCT/EP2015/080744 WO2016102437A1 (en) | 2014-12-22 | 2015-12-21 | Use of isoxazoline compounds for treating demodicosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2971296A1 true CA2971296A1 (en) | 2016-06-30 |
Family
ID=52146273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2971296A Pending CA2971296A1 (en) | 2014-12-22 | 2015-12-21 | Use of isoxazoline compounds for treating demodicosis |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20170348286A1 (https=) |
| EP (3) | EP3236960B1 (https=) |
| JP (1) | JP6706262B2 (https=) |
| CN (2) | CN106999475B (https=) |
| AU (3) | AU2015371175B2 (https=) |
| BR (1) | BR112017013286A2 (https=) |
| CA (1) | CA2971296A1 (https=) |
| DK (2) | DK4008329T3 (https=) |
| ES (2) | ES3037078T3 (https=) |
| FI (2) | FI3236960T3 (https=) |
| PL (2) | PL3236960T3 (https=) |
| PT (2) | PT4008329T (https=) |
| RU (1) | RU2709198C2 (https=) |
| WO (1) | WO2016102437A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170232024A1 (en) | 2014-08-04 | 2017-08-17 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| EP3236960B1 (en) | 2014-12-22 | 2025-01-29 | Intervet International B.V. | Fluralaner for use in the treatment of demodicosis |
| WO2018039508A1 (en) * | 2016-08-25 | 2018-03-01 | Merial, Inc. | Method for reducing unwanted effects in parasiticidal treatments |
| CN107501199A (zh) * | 2017-08-16 | 2017-12-22 | 南京农业大学 | 氟雷拉纳单体化合物的提取和纯化方法 |
| WO2019118928A1 (en) * | 2017-12-15 | 2019-06-20 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| US11880349B2 (en) | 2019-04-30 | 2024-01-23 | Salesforce, Inc. | System or method to query or search a metadata driven distributed ledger or blockchain |
| EP4077286A1 (en) | 2019-12-18 | 2022-10-26 | Elanco Tiergesundheit AG | Isoxazoline derivatives as pesticides |
| KR20230043904A (ko) | 2020-07-24 | 2023-03-31 | 엘랑코 유에스 인코포레이티드 | 이속사졸린 화합물 및 이의 중간체의 제조 공정 |
| CN116744917A (zh) | 2020-09-04 | 2023-09-12 | 礼蓝美国公司 | 适口调配物 |
| CN115785017B (zh) * | 2022-12-06 | 2023-12-08 | 海利尔药业集团股份有限公司 | 一种取代的苯酰胺异噁唑啉衍生物或其作为农药可接受的盐、组合物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2067863C1 (ru) * | 1994-05-25 | 1996-10-20 | Казанский государственный технологический университет | Акарицидный состав для лечения чесотки домашних животных |
| CN101768129B (zh) | 2004-03-05 | 2012-05-23 | 日产化学工业株式会社 | 异*唑啉取代苯甲酰胺化合物的制备中间体 |
| DE102004053964A1 (de) * | 2004-11-09 | 2006-05-11 | Bayer Healthcare Ag | Mittel gegen Demodikose |
| TWI412322B (zh) | 2005-12-30 | 2013-10-21 | Du Pont | 控制無脊椎害蟲之異唑啉 |
| TWI430995B (zh) | 2007-06-26 | 2014-03-21 | Du Pont | 萘異唑啉無脊椎有害動物控制劑 |
| KR101769728B1 (ko) | 2007-06-27 | 2017-08-18 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 동물 해충 방제 방법 |
| TWI556741B (zh) * | 2007-08-17 | 2016-11-11 | 英特威特國際股份有限公司 | 異唑啉組成物及其作為抗寄生蟲藥上的應用 |
| TWI411395B (zh) | 2007-12-24 | 2013-10-11 | Syngenta Participations Ag | 殺蟲化合物 |
| US8377942B2 (en) | 2008-12-18 | 2013-02-19 | Novartis Ag | Isoxazolines derivatives and their use as pesticide |
| HUE015568T4 (en) | 2008-12-19 | 2017-10-30 | Elanco Tiergesundheit Ag | Isoxazoline derivatives and their use as pesticides |
| NZ611474A (en) | 2010-12-27 | 2015-08-28 | Intervet Int Bv | Topical localized isoxazoline formulation comprising glycofurol |
| JP6002148B2 (ja) | 2010-12-27 | 2016-10-05 | インターベット インターナショナル ベー． フェー． | 経表面局所イソオキサゾリン製剤 |
| ME02412B (me) * | 2011-03-10 | 2016-09-20 | Zoetis Services Llc | Spirociklični derivati izoksazolina kao antiparazitska sredstva |
| RS58417B1 (sr) | 2011-09-12 | 2019-04-30 | Merial Inc | Paraziticidne kompozicije koje sadrže izoksazolinsko aktivno sredstvo, postupci i upotrebe povezane sa njima |
| EP3216448B8 (en) * | 2012-02-06 | 2019-06-05 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof |
| WO2013150055A1 (en) | 2012-04-04 | 2013-10-10 | Intervet International B.V. | Solid oral pharmaceutical compositions for isoxazoline compounds |
| WO2014090918A1 (en) * | 2012-12-13 | 2014-06-19 | Novartis Ag | Process for the enantiomeric enrichment of diaryloxazoline derivatives |
| EP3082867B1 (en) * | 2013-12-20 | 2024-01-17 | Intervet International B.V. | Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals |
| EP3236960B1 (en) | 2014-12-22 | 2025-01-29 | Intervet International B.V. | Fluralaner for use in the treatment of demodicosis |
-
2015
- 2015-12-21 EP EP15817303.9A patent/EP3236960B1/en active Active
- 2015-12-21 EP EP25179725.4A patent/EP4599830A3/en active Pending
- 2015-12-21 BR BR112017013286-9A patent/BR112017013286A2/pt not_active Application Discontinuation
- 2015-12-21 AU AU2015371175A patent/AU2015371175B2/en active Active
- 2015-12-21 ES ES21213190T patent/ES3037078T3/es active Active
- 2015-12-21 WO PCT/EP2015/080744 patent/WO2016102437A1/en not_active Ceased
- 2015-12-21 CN CN201580069964.4A patent/CN106999475B/zh active Active
- 2015-12-21 US US15/537,547 patent/US20170348286A1/en not_active Abandoned
- 2015-12-21 FI FIEP15817303.9T patent/FI3236960T3/fi active
- 2015-12-21 CA CA2971296A patent/CA2971296A1/en active Pending
- 2015-12-21 PL PL15817303.9T patent/PL3236960T3/pl unknown
- 2015-12-21 ES ES15817303T patent/ES3018234T3/es active Active
- 2015-12-21 CN CN202210404756.7A patent/CN114681453A/zh active Pending
- 2015-12-21 DK DK21213190.8T patent/DK4008329T3/da active
- 2015-12-21 JP JP2017533378A patent/JP6706262B2/ja active Active
- 2015-12-21 EP EP21213190.8A patent/EP4008329B1/en active Active
- 2015-12-21 PT PT212131908T patent/PT4008329T/pt unknown
- 2015-12-21 DK DK15817303.9T patent/DK3236960T3/da active
- 2015-12-21 PT PT158173039T patent/PT3236960T/pt unknown
- 2015-12-21 PL PL21213190.8T patent/PL4008329T3/pl unknown
- 2015-12-21 FI FIEP21213190.8T patent/FI4008329T3/fi active
- 2015-12-21 RU RU2017126029A patent/RU2709198C2/ru active
-
2018
- 2018-04-04 US US15/944,967 patent/US10799483B2/en active Active
-
2020
- 2020-09-09 US US17/015,263 patent/US20200405692A1/en not_active Abandoned
-
2021
- 2021-06-04 AU AU2021203686A patent/AU2021203686A1/en not_active Abandoned
-
2023
- 2023-08-25 AU AU2023219972A patent/AU2023219972B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023219972B2 (en) | Use of isoxazoline compounds for treating demodicosis | |
| EP3079474B1 (en) | Antiparasitic use of isoxazoline compounds | |
| AU2024278148B2 (en) | Parasite control in ruminants | |
| WO2022258797A1 (en) | Tick control methods | |
| AU2018372008B2 (en) | Composition containing moxidectin for treating parasites infestations | |
| CN103153313A (zh) | 用于防治恶丝虫侵袭的组合物 | |
| US11903962B1 (en) | Isoxazoline complexes and compositions thereof | |
| Kumar et al. | Drugs for therapeutic application in goat | |
| US20240366572A1 (en) | Isoxazoline complexes and compositions thereof | |
| WO2024059803A1 (en) | Feed and methods for controlling intestinal tract parasitic worm infections in mammals | |
| KR20230162001A (ko) | 갯과에서 진드기 감염을 방제하기 위한 경구용 갯과 사료 및 방법 | |
| JP2024513690A (ja) | 哺乳動物におけるノミおよびダニの侵入を制御する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201125 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20241119 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20241119 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250319 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250320 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250417 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250417 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250417 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250429 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250717 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250717 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251112 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251112 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260305 |